The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Antiplatelet Drugs in Cardiovascular Prevention

항혈전제의 1차 예방 및 2차 예방 효과

  • Lee, Hae-Young (Department of Internal Medicine, Seoul National University)
  • Published : 2013.07.01
⟨ Previous Next ⟩

Abstract

Hypertension and atherosclerosis are associated with a prothrombotic or hypercoagulable state, as evident by abnormalities of haemostasis, platelets and endothelial function. Therefore, in high risk hypertensive patients, use of antiplatelet agent might be beneficial in preventing thrombotic complication such as myocardial infarction and ischemic stroke. Aspirin 100 mg daily is recommended for hypertensive patients who have one of the following categories: secondary prevention ${\pm}$ cardiovascular complications, primary prevention having one of risk factors such as age > 50 years + target organ damage, a 10-year CHD risk > 15%, or type II diabetes mellitus. However, it should kept in mind that aspirin treatment be initiated after stabilization of blood pressure < 150/90 mmHg.

Keywords

References

  1. Kakar P, Lip GY. Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. Expert Rev Cardiovasc Ther 2007;5:441-450. https://doi.org/10.1586/14779072.5.3.441
  2. Lip GY, Blann AD, Edmunds E, Beevers DG. Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul. Fibrinolysis 2002;13:35-41.
  3. Agewal S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J. Hypertens 1998;16:537-541. https://doi.org/10.1097/00004872-199816040-00016
  4. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006;98:746-750. https://doi.org/10.1016/j.amjcard.2006.04.012
  5. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-2010. https://doi.org/10.1001/archinte.163.17.2006
  6. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100: 1261-1275. https://doi.org/10.1161/01.RES.0000264509.36234.51
  7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339. https://doi.org/10.1016/S0140-6736(96)09457-3
  8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. https://doi.org/10.1056/NEJMoa010746
  9. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533. https://doi.org/10.1016/S0140-6736(01)05701-4
  10. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288: 2411-2420. https://doi.org/10.1001/jama.288.19.2411
  11. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-1189. https://doi.org/10.1056/NEJMoa050522
  12. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-1232. https://doi.org/10.1001/jama.294.10.1224
  13. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366: 1607-1621. https://doi.org/10.1016/S0140-6736(05)67660-X
  14. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717. https://doi.org/10.1056/NEJMoa060989

Cited by

  1. Aspirin in the prevention of cardiovascular disease and cancer vol.57, pp.4, 2013, https://doi.org/10.5124/jkma.2014.57.4.348